MR-Linac Consortium:
Progress through
collaboration

for optimized radiation treatment

Alison Tree Consultant Clinical Oncologist

Welcome from the Chair – Alison Tree, MD

Chair of the MR-Linac Consortium Clinical Steering Committee

During the lifetime of the Consortium, we have striven to create a welcoming environment that supports and encourages research, global partnerships, and communication within our membership.

This website has been created to help you get started in our community and to understand the structure and function of the MR-Linac Consortium. It is filled with useful information that will help you understand what we do and how we are advancing the boundaries of MRinRT.
Alison Tree

Watch Alison explain the Consortium’s aims in the video below

Consortium Breakdown

The MR-Linac Consortium (the Consortium) is a collaborative platform intended to facilitate an evidence-based introduction of MRgRT and to develop and share best practices for an optimized radiation treatment approach to improve patient outcomes.

Achieving this goal is a collaboration between industry and academia. Both parties have a mutual interest in the capabilities of Unity being developed to maximize the clinical impact and the generation of high-quality evidence to demonstrate that impact. Clinical activities and publications within the Consortium are driven by participating sites and individual users. MR-Linac Consortium facilitates this clinical work by providing a platform in terms of organizational support, technical solutions and appropriate funding.

The R-IDEAL framework accelerates identification of areas where the new technology is likely to be of most benefit, and areas where the new technology is not feasible (Stage 1, 2a), not (more) effective (than standard therapy) (Stage 2b, 3) or associated with long-term adverse effects (Stage 4).

The HTP seeks to build on the volume of clinical evidence and facilitate multi-institutional relationships between users worldwide. To our knowledge, this program is the first-of-its-kind among medical technology companies, which is important because we truly believe that MRgRT is the future of radiation therapy. The HTP will enable clinicians using Unity to produce strong clinical evidence for the modality’s value. READ MORE HERE.